Related Experiment Videos
Iomeprol versus iopromide for intravenous urography
1Department of Urology, Staedtische Kliniken Kassel, Germany.
The British Journal of Radiology
|October 1, 1994
Summary
Iomeprol, a new radiographic contrast medium, demonstrated good local and systemic tolerance in a clinical trial. It showed a tendency for fewer side effects compared to iopromide during intravenous urography.
Area of Science:
- Radiology and Imaging
- Pharmacology
- Clinical Trials
Background:
- Non-ionic, tri-iodinated radiographic contrast media are essential for diagnostic imaging.
- Iopromide is a well-established, well-tolerated contrast agent.
- Evaluating new contrast media for safety and efficacy is crucial.
Purpose of the Study:
- To compare the local and systemic tolerance of iomeprol-300 with iopromide-300.
- To assess the safety profile of iomeprol-300 in patients undergoing intravenous urography.
Main Methods:
- A double-blind, randomized, phase III clinical trial.
- 198 patients requiring intravenous urography were enrolled.
- Comparison of iomeprol-300 and iopromide-300 at a standard dosage (1 ml/kg).
Main Results:
- No life-threatening adverse reactions were reported for either contrast medium.
- Sensation of heat was reported by 8% of iomeprol recipients and 6.1% of iopromide recipients.
- Nausea/vomiting occurred in 5% of patients in both groups; other side effects were generally harmless.
Conclusions:
- Iomeprol-300 is a safe radiographic contrast medium for intravenous urography.
- Iomeprol-300 exhibits a favorable tolerance profile, with a trend towards fewer side effects than iopromide.
- Further research may confirm iomeprol's superior tolerability.